A Phase I/II Open Label Study to Evaluate the Safety, Cellular Kinetics, and Efficacy of AZD0754, a Chimeric Antigen Receptor (CAR) T-cell Therapy Directed Against STEAP2, in Adult Participants With Metastatic Prostate Cancer: APOLLO
Latest Information Update: 01 May 2025
At a glance
- Drugs AZD 0754 (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions; First in man
- Acronyms APOLLO
- Sponsors AstraZeneca
Most Recent Events
- 02 Apr 2025 Planned End Date changed from 15 Jul 2027 to 30 Jun 2027.
- 02 Apr 2025 Planned primary completion date changed from 15 Jul 2027 to 30 Jun 2027.
- 03 Mar 2025 Planned End Date changed from 31 Mar 2027 to 15 Jul 2027.